Albireo Pharma IncのEBITDA margin
Albireo Pharma IncのEBITDA marginは何ですか。
Albireo Pharma IncのEBITDA marginは-195.49%です。
EBITDA marginの定義は何ですか。
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
NASDAQのセクタHealth CareにおけるEBITDA marginの企業と比べるAlbireo Pharma Inc
Albireo Pharma Incは何をしますか。
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Incと類似のebitda margin
- DubberのEBITDA marginは-196.74%です。
- Antisense TherapeuticsのEBITDA marginは-196.33%です。
- IXUPのEBITDA marginは-196.29%です。
- ImpediMedのEBITDA marginは-196.03%です。
- Amplia TherapeuticsのEBITDA marginは-195.72%です。
- Po ValleyのEBITDA marginは-195.65%です。
- Albireo Pharma IncのEBITDA marginは-195.49%です。
- WamejaのEBITDA marginは-194.84%です。
- Canadian Oil Recovery & Remediation EnterprisesのEBITDA marginは-194.76%です。
- The Cross-Harbour ()のEBITDA marginは-194.45%です。
- Insmed IncのEBITDA marginは-194.40%です。
- Palla PharmaのEBITDA marginは-194.37%です。
- Palla PharmaのEBITDA marginは-194.37%です。